Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

50 results about "Premenstrual dysphoric disorder" patented technology

A severe form of premenstrual syndrome (PMS ).

Use of progesterone receptor modulators

A progesterone receptor modulator of the structure is provided. Use of compositions containing this compound for contraception, hormone replacement therapy, treating hormone-dependent disease, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, inducing amenorrhea, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal are described.
Owner:WYETH LLC

Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof

Highly selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, visceral pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH

Novel pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
Owner:LA PHARMATECH INC

Alpha2delta ligands for fibromyalgia and other disorders

InactiveUS7164034B2Increasing slow wave sleepBiocidePeptide/protein ingredientsDiseaseOctanoic Acids
This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1or a pharmaceutically acceptable salt thereof, wherein:R1 is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; andR2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.
Owner:PFIZER INC

Serotonin and norepinephrine reuptake inhibitor and uses thereof

InactiveUS20070015824A1Low level of undesirable side-effectsBiocideOrganic chemistryNorepinephrine reuptake inhibitorDepressant
Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agoraphobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH

Systems and methods for treatment of premenstrual dysphoric disorders

ActiveUS9486243B2Avoiding unnecessary and excessive thermal treatmentUltrasound therapySurgical instruments for heatingPelvic nerveGynecology
An endoscopic procedure for the parasympathetic and sympathetic denervation of the nerves of the ovaries and uterus for management of endocrine dysphoric disorders. The tissues of selected inferior mesenteric and pelvic nerves are heated via introduction of radiofrequency energy at sufficient power and time to induce complete or partial nerve blockade while leaving the supporting tissue structurally intact. In some embodiments, the suspensory ligament of the ovary, the ovarian ligament, and / or the uterosacral ligament are heated to a range of 45° C. to 65° C. for a period of about 5 seconds to about 60 seconds.
Owner:TYCO HEALTHCARE GRP LP

Systems and methods for treatment of premenstrual dysphoric disorders

ActiveUS20130116677A1Increase temperatureAvoiding unnecessary and excessive thermal treatmentUltrasound therapySurgical instruments for heatingPelvic nerveGynecology
An endoscopic procedure for the parasympathetic and sympathetic denervation of the nerves of the ovaries and uterus for management of endocrine dysphoric disorders. The tissues of selected inferior mesenteric and pelvic nerves are heated via introduction of radiofrequency energy at sufficient power and time to induce complete or partial nerve blockade while leaving the supporting tissue structurally intact. In some embodiments, the suspensory ligament of the ovary, the ovarian ligament, and / or the uterosacral ligament are heated to a range of 45° C. to 65° C. for a period of about 5 seconds to about 60 seconds.
Owner:TYCO HEALTHCARE GRP LP

Compositions and methods for alleviating symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder

The present invention discloses pharmaceutical / nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical / nutritional compositions include at least 2% (w / w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery. Preferably, the pharmaceutical / nutritional composition further includes at least 2% (w / w) phosphatidic acid, or salts thereof, out of the total effective composition, as a first effective ingredient.
Owner:LIPOGEN

Serotonin and norepinephrine reuptake inhibitors and uses thereof

Selective dual serotonin and norepinephrine reuptake inhibitors are provided. These compounds have a lower side-effect profile and are useful in compositions and products for use in treatment of a variety of conditions including depression, fibromyalgia, anxiety, panic disorder, agorophobia, post traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, autism, schizophrenia, obesity, anorexia nervosa, bulimia nervosa, Gilles de la Tourette Syndrome, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction, borderline personality disorder, fibromyalgia syndrome, diabetic neuropathic pain, chronic fatigue syndrome, pain, Shy Drager syndrome, Raynaud's syndrome, Parkinson's Disease, and epilepsy.
Owner:WYETH LLC

Method of treating premenstrual dysphoric disorder with escitalopram

The present invention relates to a method of treating the symptoms of premenstrual dysphoric disorder (PMDD) in a patient in need thereof by administering an effective amount of escitalopram or a pharmaceutically acceptable salt thereof.
Owner:H LUNDBECK AS

Antidepressant azaheterocyclyl methyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene

Compounds of the formula useful for the treatment of such as depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder (including trichotillomania), social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addition, sexual dysfunction (including premature ejaculation), and related illnesses.
Owner:WYETH LLC

Pharmaceutical compositions and methods for treatment of psychiatric disorders

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and / or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
Owner:LA PHARMATECH INC

Premenstrual syndrome physiotherapy system based on artificial intelligence

The invention provides a premenstrual syndrome physiotherapy system based on artificial intelligence. The system capable of realizing precise laser physiotherapy for premenstrual syndrome comprises adata acquisition module, a cloud big data processing module and a laser physiotherapy module. The data acquisition module acquires biological signals of users' bodies, converts the biological signalsinto data information, and sends the data information to the cloud big data processing module. The cloud big data processing module generates corresponding image information according to the receiveddata information, processes the image information according to a deep learning technique in the artificial intelligence field to acquire users' physical information, and outputs first control signalsto the laser physiotherapy module according to the users' physical information. The laser physiotherapy module emits lasers according to the first control signals to achieve laser physiotherapy. The premenstrual syndrome physiotherapy system is applicable to physiotherapy of the premenstrual syndrome.
Owner:雷恩友力数据科技南京有限公司

Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans

Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
Owner:WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products